A prognostic biomarker is a clinical or biological characteristic that provides information on the likely patient health outcome (e.g. disease recurrence) irrespective of the treatment.
A prognostic biomarker helps indicate how a disease may develop in an individual when a disorder is already diagnosed. The presence or absence of a prognostic marker can be useful for the selection of patients for treatment but does not directly predict the response to treatment.
SGSM1 was considered to be a new prognostic biomarker for patients with LGG. And the study provided a potential therapeutic target for LGG treatment 1).
Plasma cell-free DNA (cfDNA) concentration is a promising prognostic biomarker for patients with glioblastoma. Plasma cfDNA can be obtained noninvasively and may enable more accurate estimates of survival and effective clinical trial stratification 2)